Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOXEL: Panitumumab + XELOX vs XELOX in 2nd-line mCRC
NCT00950820Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Sep 2009
- Primary completion
- Nov 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in colorectal cancer (metastatic) (mCRC), sponsored by AIO-Studien. Started Sep 2009; status: terminated.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00950820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950820.